Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Amgen K.K. to Create Independent Development, Marketing Systems
May 14, 2007
- Tokyo Municipal Hospitals Share Criteria for Selection of Generics
May 14, 2007
- Korosho Group Discusses Direct Contracts between Sponsors and Investigators
April 30, 2007
- Symposium
April 30, 2007
- R&D NEWS IN BRIEF
April 30, 2007
- India Featured at CPhi 2007
April 30, 2007
- Roche to Acquire BioVeris
April 30, 2007
- SymBio to Develop Bendamustine in Asia-Pacific Rim Countries
April 30, 2007
- MEDICAL DEVICE NEWS IN BRIEF
April 30, 2007
- BUSINESS NEWS IN BRIEF
April 30, 2007
- OINION：Times Are a Changin'
April 30, 2007
- NEW PRODUCTS
April 30, 2007
- Diabetes Care Should Be Standardized: Critical Path Seminar
April 30, 2007
- Zydus Acquires Nippon Universal
April 30, 2007
- Cancer Deaths Should Decrease by Half in Next 10 Years: Dr Kakizoe
April 30, 2007
- Generics to Be NHI Price-Listed Twice a Year from FY2007
April 30, 2007
- Korosho Study Group Issues GL on Terminal Care
April 30, 2007
- Generic Substitution Rate Remains "very Low" Despite New Prescription Form: Chuikyo
April 30, 2007
- Doctors' Average Monthly Salaries Up to \761,000
April 30, 2007
- Information on Incidence of ADRs Is Not Intellectual Property: PMDA's Mr Kishida
April 30, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…